As linkers become increasingly sophisticated, more emphasis is being placed on the methods of bioconjugation between linker and antibody, with the goal of producing homogeneous adc populations. An antibody is linked to a small molecule via a covalent tether Target, antibody, linker, payload, and conjugation method. Linker tethering payload to antibody is vital for adc This review provides an overview of linkers of 17 approved adcs and recent innovations in linker design, focusing on drug release triggers, bioconjugation strategies, the impact of spacers on hydrophilicity, traceless drug release, and linker architecture, as well as a discussion of the bystander effect, offering insights for the rational. Provides target specificity by recognizing an antigen expressed primarily on tumor cells
Chemically connects the antibody to the drug and controls its release This architecture allows adcs to function as guided missiles in oncology—homing in on cancer. An ideal linker should be stable in the circulatory system and release the cytotoxic payload specifically in the tumor
WATCH
